GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Nuveen S&P 500 Buy-Write Income Fund (NYSE:BXMX) » Definitions » Research & Development

Nuveen S&P 500 Buy-Writeome Fund (Nuveen S&P 500 Buy-Writeome Fund) Research & Development : $0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Nuveen S&P 500 Buy-Writeome Fund Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Nuveen S&P 500 Buy-Writeome Fund's Research & Development for the six months ended in Dec. 2023 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Nuveen S&P 500 Buy-Writeome Fund Research & Development Historical Data

The historical data trend for Nuveen S&P 500 Buy-Writeome Fund's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuveen S&P 500 Buy-Writeome Fund Research & Development Chart

Nuveen S&P 500 Buy-Writeome Fund Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial - - - - -

Nuveen S&P 500 Buy-Writeome Fund Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nuveen S&P 500 Buy-Writeome Fund Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuveen S&P 500 Buy-Writeome Fund  (NYSE:BXMX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nuveen S&P 500 Buy-Writeome Fund Research & Development Related Terms

Thank you for viewing the detailed overview of Nuveen S&P 500 Buy-Writeome Fund's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuveen S&P 500 Buy-Writeome Fund (Nuveen S&P 500 Buy-Writeome Fund) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Nuveen S&P 500 Buy-Write Income Fund (NYSE:BXMX) » Definitions » Research & Development
Comparable Companies
NMFC JPS RQI PDO STEW HYT VRTS ETV BDJ RVT BLK BX OSTO:INVE A TSX:BN KKR APO BK AMP XSWX:PGHN LSE:III
Traded in Other Exchanges
N/A
Address
333 West Wacker Drive, Chicago, IL, USA, 60606
Website
https://www.nuveen.com
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
Executives
Mitchell Trotta other: Portfolio Manager 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
Trey Iii Stenersen officer: Vice President 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
Brett Black officer: Chief Compliance Officer 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
John M. Mccann officer: Vice President 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
Lancellotta Amy B.r. other: Trustee 333 W. WACKER DRIVE, C/O NUVEEN, STE 3400, CHICAGO IL 60606
Joanne Medero other: Trustee 333 W. WACKER DRIVE, C/O NUVEEN, STE 3400, CHICAGO IL 60606
Matthew Iii Thornton other: Trustee 3610 HACKS CROSS ROAD, MEMPHIS TN 38125
Deann Morgan officer: Vice President TWO WORLD FINANCIAL CENTER, 7TH FLOOR, NEW YORK NY 10281
Jon Scott Meissner officer: Vice President 333 W WACKER DRIVE, STE 3400, CHICAGO IL 60606
Jacques M Longerstaey officer: Vice President 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
Brian J Lockhart officer: Vice President 333 WEST WACKER DRIVE, C/O NUVEEN STE 3400, CHICAGO IL 60606
E. Scott Wickerham officer: Vice President C/O NUVEEN, STE 3400, CHICAGO IL 60606
Demark L Winget officer: Vice President C/O NUVEEN INVESTMENTS, 333 W WACKER DRIVE, CHICAGO IL 60606
William T. Meyers officer: Vice President C/O NUVEEN, 333 W. WACKER DRIVE, CHICAGO IL 60606
Michael A Perry officer: Vice President 101 PARK AVENUE, SUITE 1400, OKLAHOMA CITY OK 73102